Human Genome Sciences, GlaxoSmithKline deal

GSK exercised an option to develop and commercialize mapatumumab ( HGS-ETR1) with HGSI. The companies will share equally in Phase III and IV development costs, sales and marketing expenses and profits on any commercialized products. The TRM-1 antibody agonist of tumor necrosis factor-related apoptosis-inducing ligand receptor-1 ( TRAIL-R1) has completed a Phase II trial to treat non-small cell lung cancer (NSCLC) and is in Phase II testing to treat non-Hodgkin's lymphoma (NHL) and colorectal cancer. Results from the NHL and colorectal cancer trials are expected this year. ...